[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578752":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Almirall, S.A.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants with atopic dermatitis and treated with lebrikizumab (Ebglyss®) according to Summary of Product Characteristics (SmPC) in routine clinical practice, data will be collected and observed for 104 weeks.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is non-interventional study.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Èric Massana","CONTACT","0034 932 913 986","eric.massana@almirall.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Aarhus University Hospital","RECRUITING","Aarhus","Denmark","DK",{"type":34,"coordinates":35},"Point",[36,37],10.21076,56.15674,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":10,"phoneExt":10,"email":10},"Dr. Christian Vestergaard","PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100578752","a-study-to-assess-the-impact-of-lebrikizumab-on-health-related-well-being-and-control-of-skin-manifestations-in-participants-with-moderate-to-severe-atopic-dermatitis-100578752",false,"NCT06815380","A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis","A European, Multicenter, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Patients With Moderate-to-Severe Atopic Dermatitis","ADTrust","Inclusion Criteria:\n\n* Adult (greater than or equal to \\[\\>=\\] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis.\n* Adult participants prescribed lebrikizumab as part of routine\u002Fusual care to manage their moderate-to severe Atopic dermatitis.\n* Willingness and ability to participate in the study; participants must give their written consent to participate.\n\nExclusion Criteria:\n\n* Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss®).\n* Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy.\n* Concomitant use of live and live attenuated vaccines.\n* Pregnant women, except when the potential benefit justifies the potential risk.\n* Participants included in a clinical trial at baseline or at any time during the planned study period.\n* Participants unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study.\n* Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.","ALL","18 Years",{"count":56,"type":57},1000,"ESTIMATED","OBSERVATIONAL","The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured using validated 5-item World Health Organization Well-being Index (WHO-5) and to investigate effectiveness and safety of lebrikizumab, treatment satisfaction, and long-term effect of lebrikizumab treatment on participants in terms of disease symptomatology\u002Fcontrol, fatigue, work impairment, patient's relationship with their skin, and overall QOL among adult participants.",[61,62],"Atopic Dermatitis","Eczema","2025-02-04",{"date":65,"type":66},"2025-02-07","ACTUAL",{"date":68,"type":66},"2025-01-23",{"date":70,"type":57},"2029-03",{"name":5,"class":6},1]